The Stock Watcher
Sign InSubscribe

IgGenix Raises $40 Million Series B Led by Alexandria Venture Investments

Share this article

IgGenix, a startup developing therapeutics for severe allergies, has raised a $40 million Series B led by Alexandria Venture Investments.

alexandria venture investments

Alexandria Venture Investments, an S&P 500® company, recently led a Series B round of $40 million for IgGenix, a startup developing therapeutics for severe allergies. The round was also joined by Eli Lilly and Company, as well as existing investors Khosla Ventures, Aisling Capital, Sectoral Asset Management, Mass General Brigham Ventures, and Alexandria Venture Investments.

Alexandria Venture Investments is a best-in-class, mission-driven life science REIT with the goal of making a positive and lasting impact on the world. The company has made a name for itself by investing in and supporting emerging life science companies in the form of venture capital, mezzanine debt, and other Investments.

IgGenix, founded in 2019, is focused on developing novel therapies for severe allergies, including peanut and other tree nut allergies. The company has raised a total of $75 million in venture capital funding to date, including the $40 million Series B round that Alexandria Venture Investments led.

The Series B funding will be used to advance IgGenix's drug development program, which includes the development and clinical testing of its lead product, a peanut allergen-specific immunotherapy (ASIT). The funding will also be used to support the company's preclinical and clinical development activities.

Alexandria Venture Investments' investment in IgGenix is part of the company's broader mission to support life science companies and help them create innovative treatments and therapies. The company has invested in a number of life science startups, including Syncona, which recently saw a “disappointing” drop in its share price due to its Investments in gene therapy companies.

In January 2023, Alexandria Venture Investments was recognized by Silicon Valley Bank in its 'Healthcare Investments and Exits: Annual Report.' The report highlighted the firm's commitment to investing in life sciences and its success in helping startups reach their goals.

Alexandria Venture Investments has also made Investments in a number of preclinical biotech companies, including AllerFund and other unnamed investors. The funding rounds for these companies have pulled in Big Pharma investors and venture capital firms, allowing them to expand their operations and create more treatments and therapies.

Alexandria Venture Investments' commitment to investing in life sciences has helped it become one of the leading venture capital firms in the industry. The company's Investments have helped many startups reach their goals and create innovative treatments and therapies for a range of diseases and conditions.


May Interest You

Share this article
3640 Concord Pike Wilmington, DE 19803
About TheStockWatcher
© 2023 - TheStockWatcher. All Rights Reserved